Olanzapine News and Research

RSS
Olanzapine (trade names Zyprexa, Zyprexa Zydis, Zalasta, Zolafren, Olzapin, Rexapin or in combination with fluoxetine Symbyax) is an atypical antipsychotic, approved by the FDA for the treatment of schizophrenia and bipolar disorder.
Janssen announces submission of NDA for three-month paliperidone palmitate

Janssen announces submission of NDA for three-month paliperidone palmitate

Alkermes initiates second ALKS 3831 Phase 2 clinical study for treatment of schizophrenia

Alkermes initiates second ALKS 3831 Phase 2 clinical study for treatment of schizophrenia

Mylan releases generic version of Zyprexa Zydis Tablets

Mylan releases generic version of Zyprexa Zydis Tablets

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Antipsychotic drugs for children with behavioral problems may put at risk for type 2 diabetes

Antipsychotic drugs for children with behavioral problems may put at risk for type 2 diabetes

Alkermes reports positive results from phase 1 study of ALKS 3831 for treatment of schizophrenia

Alkermes reports positive results from phase 1 study of ALKS 3831 for treatment of schizophrenia

Off label atypical antipsychotic use lacks safety and effectiveness in patients over 40

Off label atypical antipsychotic use lacks safety and effectiveness in patients over 40

FDA accepts Sunovion’s two LATUDA sNDAs for review

FDA accepts Sunovion’s two LATUDA sNDAs for review

Adjunctive drugs hasten sedation in the emergency department

Adjunctive drugs hasten sedation in the emergency department

Antipsychotic use in pregnancy should be closely monitored

Antipsychotic use in pregnancy should be closely monitored

Gestational diabetes may be more likely with antipsychotic use

Gestational diabetes may be more likely with antipsychotic use

Teva launches Olanzapine and Fluoxetine Capsules for treatment of depression

Teva launches Olanzapine and Fluoxetine Capsules for treatment of depression

Sunovion announces results from LATUDA open-label study for schizophrenia

Sunovion announces results from LATUDA open-label study for schizophrenia

Teva first quarter net revenues increase 25% to $5.1 billion

Teva first quarter net revenues increase 25% to $5.1 billion

Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

Mylan receives final FDA approval for generic Zyprexa ANDA

Mylan receives final FDA approval for generic Zyprexa ANDA

Olanzapine improves survival in mouse model of anorexia nervosa

Olanzapine improves survival in mouse model of anorexia nervosa

Weight gain or loss may also depend on medicines taken

Weight gain or loss may also depend on medicines taken

Dr. Reddy’s third quarter revenues increase 46% to $522 million

Dr. Reddy’s third quarter revenues increase 46% to $522 million

New report finds little evidence to support off-label use of atypical antipsychotics

New report finds little evidence to support off-label use of atypical antipsychotics